Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 8/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 2/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15071123 | 0.84 | HPGD (0.56) | HPGDNPC1ALDH1A1GLARAB9A | |
| SCHEMBL15071121 | 0.83 | HPGD (0.54) | HPGDNPC1ALDH1A1GLARAB9A | |
| SCHEMBL31525 | 0.80 | HPGD (0.77) | HPGDNPC1ALDH1A1GLARAB9A | |
| SCHEMBL15071119 | 0.73 | MKNK1 (0.52) | HPGDMKNK1MKNK2KMT2A | |
| SCHEMBL15071118 | 0.72 | MKNK1 (0.53) | HPGDMKNK1MKNK2 | |
| SCHEMBL31560 | 0.71 | F2RL1 (0.63) | HPGDNPC1ALDH1A1GLARAB9A | |
| SCHEMBL10174633 | 0.70 | HPGD (1.00) | HPGDNPC1ALDH1A1RAB9AKMT2A | |
| SCHEMBL12969 | 0.70 | HPGD (1.00) | HPGDNPC1ALDH1A1RAB9AKMT2A | |
| SCHEMBL31554 | 0.70 | MKNK1 (0.63) | MKNK1MKNK2 | |
| SCHEMBL15071141 | 0.70 | F2RL1 (0.61) | HPGDNPC1ALDH1A1GLARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165652-A1 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | NEOPHARM CO.,LTD. (KR) | 2013-06-27 | — | — | US | disclosed |
| US-20130165652-A1 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | NEOPHARM CO.,LTD. (KR) | 2013-06-27 | — | — | US | disclosed |
| WO-2012026765-A2 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | (주)네오팜 (KR) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165652-A1 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | F2RL1, F2R, FPR2 | HPGD 80/4885NPC1 2008/4885ALDH1A1 3710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.